• January 18, 2021

Tempus Announces Companion Diagnostic Collaboration With A2 Biotherapeutics - Odessa American: Business

e-Edition Subscribe

Tempus Announces Companion Diagnostic Collaboration With A2 Biotherapeutics

Print
Font Size:
Default font size
Larger font size

Posted: Wednesday, January 13, 2021 1:06 pm | Updated: 1:32 pm, Wed Jan 13, 2021.

CHICAGO--(BUSINESS WIRE)--Jan 13, 2021--

Tempus, a leader in artificial intelligence and precision medicine, today announced a strategic collaboration to develop a companion diagnostic (CDx) test with A2 Biotherapeutics for its new therapy targeting patients with Loss of Heterozygosity (LOH). It is anticipated that this collaboration could also provide a platform for the development of further CDx tests for A2’s other clinical development programs, which is part of its innovative approach to accelerate drug development.

A2, a biotechnology company developing innovative cell therapies for cancer patients with solid tumors, is collaborating with Tempus to validate its leading xT sequencing assay to specifically identify patients with the LOH genetic alteration. This new diagnostic test is part of A2’s initiative to use its next-generation cell therapy Tmod TM platform to revolutionize the treatment of solid tumor cancers, engineering T cells that target the loss of genetic material in tumors and enable the selective killing of tumor cells while leaving normal cells unharmed.

“We believe that our proprietary platform is ideal for companion diagnostic collaborations,” said Michael Yasiejko, Chief Commercial Officer. “We look forward to furthering A2’s efforts in identifying patients with this unique biomarker, and ultimately advance Tempus’ work with leading pharmaceutical and biotech companies in therapeutic development.”

“We identified Tempus as the ideal collaborator for this CDx given its smart genomic testing platform and the scope of its dataset,” said William Go, MD, PhD, Senior Vice President and Head of Development at A2 Biotherapeutics. “Together, we aim to identify those patients who could potentially benefit from this investigational Tmod therapy and further our goal in making a difference in solid tumor cancers.”

Tempus’ immunotherapy platform is uniquely comprehensive and provides information including, but not limited to: immune infiltration, neoantigen prediction, tumor mutational burden (TMB), microsatellite instability (MSI), HLA typing, HLA loss of heterozygosity, TCR & BCR repertoire, and oncoviral detection.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20210113005824/en/

CONTACT: Erin Carron

Director of Communications

erin.carron@tempus.com

KEYWORD: UNITED STATES NORTH AMERICA ILLINOIS

INDUSTRY KEYWORD: DATA MANAGEMENT HEALTH TECHNOLOGY SOFTWARE PHARMACEUTICAL HARDWARE BIOTECHNOLOGY

SOURCE: Tempus

Copyright Business Wire 2021.

PUB: 01/13/2021 02:05 PM/DISC: 01/13/2021 02:06 PM

http://www.businesswire.com/news/home/20210113005824/en

© 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Odessa, TX

Current Conditions

Sunny
62°
Humidity: 20%
Winds: NNE at 16mph
Feels Like: 60°

Your Extended Forecast

Today

weather
High 73°/Low 36°
Mainly clear. Lows overnight in the mid 30s.

Tomorrow

weather
High 44°/Low 36°
Mostly cloudy. Highs in the mid 40s and lows in the mid 30s.

wednesday

weather
High 46°/Low 39°
Showers ending by midday. Highs in the mid 40s and lows in the upper 30s.

thursday

weather
High 63°/Low 47°
Mostly cloudy. Highs in the low 60s and lows in the upper 40s.
Online Features

Pet Central

pets

Having a pet is a lot of responsibility, and we’ll help by giving you lots of tips and tricks! More >>

Fitness

Fitness

Our fitness articles will help teach you how to work out with gym- and home-based exercises. More >>

Crosswords

Crosswords

Enjoy the crosswords challenge in our free daily puzzles, from the harder Sunday crossword to the quicker daily. More >>

Sudoku

Sudoku

Every Sudoku has a unique solution that can be reached logically. Enter numbers into the blank spaces so that each row, column and 3x3 box contains the numbers 1 to 9. More >>




  • ALL-ACCESS: Subscribe to our e-edition and premium website at myoaoa.com.
    You can read your daily newspaper without taking a walk to the driveway.
    Look back at yesterday's newspaper, or issues from months ago with our archive feature.
    Call circulation at 432-337-7314 to sign up today.